Category literacy

Knee, Hip Or Hand: Where The Joint Trials Have Actually Looked

Almost every supplement trial in this category was run on knees. If your problem is a hip, a shoulder or a set of fingers, you are extending a knee result to a joint nobody studied, and no label in this aisle will mention it. Here is the map.

By Artivorin Team · Last updated October 29, 2026 · 8 min read · Category literacy · Reviewed by Dr. Blake Peterson, MD

Why one joint dominates the research

There is no conspiracy in this and the explanation is dull, which is usually a good sign.

Knee osteoarthritis is common, it is easy to define for a trial, and there are validated scoring instruments for measuring it that everybody in the field accepts. A researcher designing a study wants a condition with a large eligible population and an outcome measure the journals will accept, and the knee provides both.

Hands are harder to score, hips are harder to enrol and shoulders bring a much wider set of possible causes with them. So the trials cluster, and thirty years later the literature in a whole category is about one joint.

The consequence is not that other joints are unaffected by what these ingredients do. It is that nobody has checked, and a page that talks about joints in general is quietly generalising from a body of work about one of them.

What the trials actually enrolled

Every row says knee. That is not a selection made by this page; it is what the literature contains.

The 2014 curcuminoid trial enrolled patients with knee osteoarthritis. The 367-patient comparison against ibuprofen did the same, as did the earlier pilot five years before it.

The 2024 review of eleven meta-analyses and the 2025 network meta-analysis both pool that work, which means they inherit its shape. A review of knee trials is a review about knees however many patients it contains.

That is worth saying plainly because the size of those numbers does a lot of work in marketing copy. Thirty-nine trials and 4,599 patients sounds like a literature covering everything, and it is a literature covering one joint very thoroughly.

Reading it against your own joint

Rows two to five are not reasons not to buy anything. They are reasons to know that you are extending a result rather than relying on one.

The first row is the straightforward case. If your problem is a knee, the research in this category is about you, and the main question left is the one about amounts.

The middle rows are the interesting ones. Extending a result from a knee to a hip is not unreasonable: both are load-bearing, both are covered by the same clinical guideline, and the proposed mechanisms are not joint-specific. It is still an extension, and knowing that you are making one changes how much confidence to place in it.

The last row is the one where a purchase should probably wait. Several joints at once, particularly with morning stiffness lasting more than an hour, is a pattern worth having looked at rather than supplementing.

What does and does not carry across between joints

Extending a result is not guesswork, and it is not proof either. It is worth being precise about which parts of the reasoning travel.

The mechanism travels reasonably well. Whatever an anti-inflammatory botanical does, it does systemically rather than to one named joint, so there is no obvious reason a knee would respond and a hip would not. That is the strongest argument for extension and it is a real one.

The loading does not travel. A knee and a hip carry bodyweight and a finger joint does not, so an intervention whose effect runs partly through load is in a different situation in each. That is also why the free interventions rank where they do.

The measurement does not travel either, and this is the part most often forgotten. The questionnaires used in knee trials ask about stairs, walking and getting out of a chair. Nothing in those questions is about buttons, jars or a keyboard, so even a successful hand trial would have to measure something different to mean anything.

• Mechanism carries across between joints reasonably well.
• Load-bearing does not, and it separates knees and hips from hands and wrists.
• The scoring instruments do not, which is part of why the trials have not been run.
• Your own notes carry across perfectly, because you are measuring your own joint.
• That last line is the argument for writing something down on day one.

What the guideline covers that the trials do not

The 2019 rheumatology guideline is titled for the hand, the hip and the knee, which tells you immediately that the clinical world takes all three seriously even where the supplement trials have not followed.

Its first-line recommendations, exercise and weight management, apply across those joints rather than to one. That is a useful asymmetry to notice: the free interventions have the broader evidence base as well as the stronger one.

MedlinePlus covers what osteoarthritis is across the body in plain language, and is a better first read than any supplement page including this one.

A note on hands specifically

Hand osteoarthritis is common, it affects things people do constantly, and it is very poorly served by the supplement literature. Anybody buying a joint product for their hands is extending a knee result further than anybody buying for a hip.

That is worth knowing rather than discovering. It does not mean nothing will happen; it means there is no published basis for predicting that it will.

When a joint problem is a different problem

• A joint that is hot to the touch, or visibly swollen, or red.
• A joint that locks, gives way or has become severely painful over days rather than years.
• Morning stiffness that lasts more than an hour rather than a few minutes.
• Several joints becoming painful at once, particularly symmetrically.
• Any joint pain with a fever, a rash or unexplained weight loss.

Each of those is a reason to be assessed rather than a reason to start a capsule, and none of them is rare. A supplement cannot distinguish between the several things that make a joint hurt, and sixty days spent waiting for one to work is sixty days not spent finding out which one you have.

This is the least commercial paragraph on this website and it is on a blog run by a seller, which should tell you something about how strongly this desk means it.

How to decide when the research is about somewhere else

1. Establish which joint, and whether it matches the trials. Knee is a direct match, hip is an extension, hand is a longer one.
2. Check the pattern against the list above, and get assessed first if anything on it applies.
3. Set your expectation by the strength of the match. A weaker match means a genuinely lower probability, not a different product.
4. Buy the pack that matches the refund window rather than the cheapest one per bottle.
5. Judge it at six weeks against notes you wrote on day one.

Step three is the one worth dwelling on. Most disappointment in this category comes from expectations set by a label rather than by a literature, and the correction is not pessimism. It is simply matching what you expect to what has actually been studied, which is what the category guide on this website exists to make possible.

References